DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contributio

Friday, 6 March 2015

Dr. Michael Buschle

Dr Michael Buschle
Chief Scientific Officer, Glenmark Pharmaceuticals Ltd.


University Of London

University of London

Other Affiliations

Local Address: La Chaux-de-Fonds, Switzerland
Glenmark Pharmaceuticals Limited 
750 Corporate Drive 
Mahwah , New Jersey 07430
United States 

Dr. Michael Buschle has been Chief Scientific Officer of Glenmark Pharmaceuticals Ltd. Dr. Buschle serves as President for Biologics Research at Glenmark Pharmaceuticals S.A. 

He served as President for Biologics Research at Glenmark Pharmaceuticals Ltd. Mr. Buschle served as Chief Scientific Officer of Intercell Biomedical Research & Development AG. Dr. Buschle served as Director and Managing Director of Intercell Biomedical Ltd., a subsidiary of Intercell AG. 

He served as Chief Technical Officer of Intercell AG, since November 2004 and prior to this served as Chief Scientific Officer. Dr. Buschle served as a Member of Management Board of Intercell Biomedical Research & Development AG until October 24, 2005. 

Dr Michael Buschle

Mr. Buschle scientific and industrial career includes work at Royal Free Hospital School of Medicine, London, UK, the St. Jude Children’s Research Hospital, Memphis, TN, USA and at pharmaceutical company Boehringer Ingelheim. He was one of the co-founders of Intercell AG. During his time at Boehringer Ingelheim, he was involved in the development of a cancer vaccine against malignant melanomas. Mr. Buschle is the holder of several patents in the field of vaccines and biotechnology. 

Mr. Buschle is responsible for its Core Research activities leading to development candidates. Dr. Buschle has over 12 years of pharmaceutical/biotech industry experience in areas including drug research and development and biopharmaceuticals manufacturing. Dr. Buschle holds a doctorate from the University of London.

Dr Anthony crasto With Dr Michael Buschle end 2014

Dr. Michael Buschle is Chief Scientific Officer at Glenmark Pharmaceuticals Ltd.

Dr. Buschle was previously employed as Co-Founder by Intercell AG.

Current positions of Michael Buschle, PhD
 Glenmark Pharmaceuticals Ltd
Chief Scientific Officer2012

Company Description: 
Glenmark US Operations Glenmark Pharmaceuticals has established its US subsidiary, based in Princeton, New Jersey, Glenmark Pharmaceuticals Inc., USA, to help file ANDAs and market finished formulations in the lucrative US market. Glenmark Pharmaceuticals Inc., USA will file Paragraph III and Paragraph IV ANDA filings for approval to market generic drugs, and work in tandem with other companies in marketing partnerships, to establish market penetration and substantial marketshare in the US market. Glenmark will make a number of such filings over the next 18 to 24 months. Further the company will register its bulk drugs - the key ingredients that lend medicines their potency - with the US Food & Drug Administration. It plans four to five drug master filings in the US this year, with the first likely to happen in the second quarter ending September. With these strategic initiatives underway, the Company is aggressively looking at additional strategic partnerships with other leading generic drug companies with a strong US presence.


Published on 21 Aug 2014
Mint met with Michael Buschle, Chief Scientific Officer & President of Biologics, Glenmark Pharmaceuticals to discuss costs, challenges and selecting regions for trials in India.

“Researchers at Glenmark focus on developing monoclonal antibodies. Glenmark is the first Indian company that has a novel, first-in-class novel biologic entity in the clinics in the US. We are establishing platform technologies to develop biologics in a format specific for Glenmark”
-Dr Michael Buschle, president (biologics), Glenmark Pharmaceuticals
- See more at: http://www.biospectrumindia.com/biospecindia/news/158971/master-innovation#sthash.k9A3A07N.dpuf

MD and CEO Glenn Saldanha with Michael Buschle, President Biologics, Glenmark Pharmaceuticals Ltd.



Mahwah , New Jersey 

  1. Map of mahwah nj
  2. Mahwah
    Township in New Jersey

dollar 22 Million English Manor in Mahwah New Jersey

La Chaux-de-Fonds, Switzerland

  1. Map of la chaux de fonds
      • Image result for La Chaux-de-Fonds, Switzerland
  2. La Chaux-de-Fonds

      • Image result for intercell ag
  1. Intercell
    Biotechnology company
  2. Intercell AG was a biotechnology company based in Vienna which focuses on the development of modern prophylactic and therapeutic vaccines against infectious diseases. Wikipedia
  3. Founded1998

No comments:

Post a Comment